Items where Author is "Kuhle, J."

(2026) Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry. Therapeutic Advances in Neurological Disorders. p. 17562864261430084. ISSN 1756-2856 (Print) 1756-2864 (Electronic) 1756-2856 (Linking)

(2026) Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry. Journal of Neurology. p. 15. ISSN 0340-5354

(2026) Predicting disease progression in multiple sclerosis with clinically accessible information and technology. Journal of Neurology. p. 18. ISSN 0340-5354

(2025) Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. pp. 50-58. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Multiple Sclerosis Journal-Experimental Translational and Clinical. p. 13.

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) A Multi-Country Comparative Effectiveness Study of Dimethyl Fumarate and Non-Specific Immunosuppressants in a Real-World Setting: Evidence from MSBase. Multiple Sclerosis Journal. NP29-NP30. ISSN 1352-4585

(2022) Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 947-950. ISSN 1352-4585

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2021) Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Comput Methods Programs Biomed. p. 106180. ISSN 0169-2607

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)